Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 36

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 36
---
. Accordingly, the Company needs stockholder approval of the issuance of shares of Common Stock upon the exercise of the February 2025 Common Warrants. On the Record Date, assuming the issuance of all shares of Common Stock upon the exercise of all of the February 2025 Common Warrants, the February 2025 Investors would own approximately 5,102,040shares of Common Stock, assuming continued ownership of the shares of Common Stock acquired thereby in the February 2025 Registered Direct Offering and/or pursuant to exercises of Pre -FundedWarrants (as defined below), but excluding any securities acquired other than through such February 2025 Registered Direct Offering. Such shares would constitute approximately 36.6% of the then -outstandingCommon Stock after the issuance of such shares. In addition, under the terms of the February 2025 Common Warrants, an Investor may not exercise the February 2025 Common Warrants to the extent (but only to the extent) such Investor or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99%, or, at the election of the Investor, a number of shares of Common Stock which would exceed 9.99%. 17

February 2025 Registered Direct Offering In February 2025, the Company consummated the February 2025 Registered Direct Offering of 300,000shares of Common Stock, 2,251,020 pre -fundedwarrants to purchase shares of Common Stock at an exercise price of $0.0001 per share (“Pre -FundedWarrants”) and 2,551,020 February 2025 Common Warrants, pursuant to the Securities Purchase Agreement, dated February 5, 2025, by and among the Company and certain Investors, for aggregate cash proceeds to the Company of approximately $5 million. Description of Securities See “ Description of Capital Stock” for a description of the Pre -FundedWarrants and February 2025 Common Warrants. Impact on Stockholders of Approval or Disapproval of this Proposal If this proposal is approved, existing stockholders will suffer dilution in ownership interests and voting rights as a result of the issuance of shares of Common Stock upon the exercise of the February 2025 Common Warrants. Assuming the issuance of all shares of Common Stock upon the exercise of all of the Pre -FundedWarrants and February 2025 Common Warrants, the February 2025 Investors would own approximately 5,102,040shares of Common Stock